Stephanie L. Graff, MD FACP FASCO
@drsgraff.bsky.social
Director Breast Oncology, Brown University Health Cancer Institute, Legorreta Cancer Center Brown Univ| #bcsm #clinicaltrials #oncology | Views Mine
VERITAC-2 shows vepdegestrant improves PFS after CDK4/6i among pts with HR+ mutESR1 MBc, from 2.1 months to 5.0 months. @erikahamilton9.bsky.social
@oncoalert.bsky.social #ASCO25
@oncoalert.bsky.social #ASCO25
May 31, 2025 at 7:00 PM
VERITAC-2 shows vepdegestrant improves PFS after CDK4/6i among pts with HR+ mutESR1 MBc, from 2.1 months to 5.0 months. @erikahamilton9.bsky.social
@oncoalert.bsky.social #ASCO25
@oncoalert.bsky.social #ASCO25
Reflex cDNA-methylation multi-cancer early detection (MCED) test achieved meaningful per-cancer intrinsic accuracy & per-tissue of origin PPV across mult cancer types evaluated in at-risk indiv w/obesity. #ASCO25 @oncoalert.bsky.social
May 31, 2025 at 1:47 PM
Reflex cDNA-methylation multi-cancer early detection (MCED) test achieved meaningful per-cancer intrinsic accuracy & per-tissue of origin PPV across mult cancer types evaluated in at-risk indiv w/obesity. #ASCO25 @oncoalert.bsky.social
The chemo-free combo of Ribo+Let+trastuzumab led to mOFS 30.4 months, good ORR, and minimal cardiac toxicity in this ph2 1L Korean study. #ASCO25 @oncoalert.bsky.social
May 30, 2025 at 8:30 PM
The chemo-free combo of Ribo+Let+trastuzumab led to mOFS 30.4 months, good ORR, and minimal cardiac toxicity in this ph2 1L Korean study. #ASCO25 @oncoalert.bsky.social
Dr. @hoperugo.bsky.social presents data from 5️⃣ 🇺🇸centers on re-challenge after G1 ILD with T-DXd (n=44), and a small # (n=19) G2 ILD rechallenged.
27% of G1 rechallenged had a second event; 16% of the G2 patients had a second event #ASCO25
@oncoalert.bsky.social
27% of G1 rechallenged had a second event; 16% of the G2 patients had a second event #ASCO25
@oncoalert.bsky.social
May 30, 2025 at 8:12 PM
Dr. @hoperugo.bsky.social presents data from 5️⃣ 🇺🇸centers on re-challenge after G1 ILD with T-DXd (n=44), and a small # (n=19) G2 ILD rechallenged.
27% of G1 rechallenged had a second event; 16% of the G2 patients had a second event #ASCO25
@oncoalert.bsky.social
27% of G1 rechallenged had a second event; 16% of the G2 patients had a second event #ASCO25
@oncoalert.bsky.social
Kicking off breast sessions #ASCO25 with the data that Black patients with breast cancer continue to have worse overall survival in the modern-HER2 era. Adjusted HR 1.28 @oncoalert.bsky.social
May 30, 2025 at 7:55 PM
Kicking off breast sessions #ASCO25 with the data that Black patients with breast cancer continue to have worse overall survival in the modern-HER2 era. Adjusted HR 1.28 @oncoalert.bsky.social
Join me & Maryam Lustberg at #ASCO25 at #OncForum2025 to discuss ADCs, sequencing, HER2 low/ultra-low, biomarkers, and “right-sizing” early stage disease
Saturday June 1 at 7:15- 7:45 PM
Duneyrr Fermenta & Brewery
2337 S. Michigan Ave.
Register now! app.smartsheet.com/b/form/7e557...
Saturday June 1 at 7:15- 7:45 PM
Duneyrr Fermenta & Brewery
2337 S. Michigan Ave.
Register now! app.smartsheet.com/b/form/7e557...
May 24, 2025 at 10:38 AM
Join me & Maryam Lustberg at #ASCO25 at #OncForum2025 to discuss ADCs, sequencing, HER2 low/ultra-low, biomarkers, and “right-sizing” early stage disease
Saturday June 1 at 7:15- 7:45 PM
Duneyrr Fermenta & Brewery
2337 S. Michigan Ave.
Register now! app.smartsheet.com/b/form/7e557...
Saturday June 1 at 7:15- 7:45 PM
Duneyrr Fermenta & Brewery
2337 S. Michigan Ave.
Register now! app.smartsheet.com/b/form/7e557...
Honored and humbled to be awarded the 2025 E. Grey Diamond Take Wing Award, my school’s highest alumni honor. Thank you, Dean Norbash, my amazing family, members of the awards committee— I am proud to embody the spirit of UMKC SOM in all that I do.
May 16, 2025 at 9:13 PM
Honored and humbled to be awarded the 2025 E. Grey Diamond Take Wing Award, my school’s highest alumni honor. Thank you, Dean Norbash, my amazing family, members of the awards committee— I am proud to embody the spirit of UMKC SOM in all that I do.
In <1 minute, use @ascocancer.bsky.social link to #ProtectMedicaid. Maybe you think it isn’t about you—but sometimes patients w/cancer lose their job, insurance is tied to employment, then suddenly—Medicaid is about them. Urge members of congress to safeguard Medicaid ➡️brnw.ch/21wSxkd
May 10, 2025 at 12:23 AM
In <1 minute, use @ascocancer.bsky.social link to #ProtectMedicaid. Maybe you think it isn’t about you—but sometimes patients w/cancer lose their job, insurance is tied to employment, then suddenly—Medicaid is about them. Urge members of congress to safeguard Medicaid ➡️brnw.ch/21wSxkd
I just had to explain the expression “burning the candle at both ends” to my 9yo. But, yep. #currentsituation
April 16, 2025 at 10:29 PM
I just had to explain the expression “burning the candle at both ends” to my 9yo. But, yep. #currentsituation
An honor to meet w/Rep.Magaziner staff, Raisa Majid with Drs. Mega & Strenger to discuss key #ASCOAdvocacySummit asks including consistent funding for the NIH, NCI, and ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug
Shortages. @ascocancer.bsky.social
Shortages. @ascocancer.bsky.social
April 8, 2025 at 7:43 PM
An honor to meet w/Rep.Magaziner staff, Raisa Majid with Drs. Mega & Strenger to discuss key #ASCOAdvocacySummit asks including consistent funding for the NIH, NCI, and ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug
Shortages. @ascocancer.bsky.social
Shortages. @ascocancer.bsky.social
I am joining over 150 oncologists this week at the #ASCOAdvocacySummit in Washington, D.C. to urge Congress to help address existing #drugshortages and prevent future shortages of lifesaving and life-prolonging cancer drugs. @ascocancer.bsky.social
April 8, 2025 at 6:15 PM
I am joining over 150 oncologists this week at the #ASCOAdvocacySummit in Washington, D.C. to urge Congress to help address existing #drugshortages and prevent future shortages of lifesaving and life-prolonging cancer drugs. @ascocancer.bsky.social
Had delightful meeting w/Sen. Whitehouse staffer Joe Page
w/Drs Mega & Strenger to discuss key #ASCOAdvocacySummit key asks incld consistent funding for the NIH, NCI & ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug Shortages @ascocancer.bsky.social
w/Drs Mega & Strenger to discuss key #ASCOAdvocacySummit key asks incld consistent funding for the NIH, NCI & ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug Shortages @ascocancer.bsky.social
April 8, 2025 at 6:12 PM
Had delightful meeting w/Sen. Whitehouse staffer Joe Page
w/Drs Mega & Strenger to discuss key #ASCOAdvocacySummit key asks incld consistent funding for the NIH, NCI & ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug Shortages @ascocancer.bsky.social
w/Drs Mega & Strenger to discuss key #ASCOAdvocacySummit key asks incld consistent funding for the NIH, NCI & ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug Shortages @ascocancer.bsky.social
ASCO CEO Cliff Hudis joined #RhodeIsland’s #ASCOAdvocacySummit delegates Drs.Mega, Strenger & I meeting w/Senator Reed Our key asks incld consistent funding for NIH, NCI & ARPA-H; the Improving Seniors' Timely Access to CareAct; partnering on a Solution to End DrugShortages @ascocancer.bsky.social
April 8, 2025 at 6:05 PM
ASCO CEO Cliff Hudis joined #RhodeIsland’s #ASCOAdvocacySummit delegates Drs.Mega, Strenger & I meeting w/Senator Reed Our key asks incld consistent funding for NIH, NCI & ARPA-H; the Improving Seniors' Timely Access to CareAct; partnering on a Solution to End DrugShortages @ascocancer.bsky.social
An honor to meet w/ #RepGabeAmo this AM w/Drs. Mega & Strenger to discuss key #ASCOAdvocacySummit asks including consistent funding for the NIH, NCI, and ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a
Comprehensive Solution to End Drug Shortages. @ascocancer.bsky.social
Comprehensive Solution to End Drug Shortages. @ascocancer.bsky.social
April 8, 2025 at 5:51 PM
An honor to meet w/ #RepGabeAmo this AM w/Drs. Mega & Strenger to discuss key #ASCOAdvocacySummit asks including consistent funding for the NIH, NCI, and ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a
Comprehensive Solution to End Drug Shortages. @ascocancer.bsky.social
Comprehensive Solution to End Drug Shortages. @ascocancer.bsky.social
#RhodeIsland’s own Anthony Mega engaging with the #ASCOAdvocacySummit team around ways oncology clinicians can advocate for prior authorization reform thru Improving Seniors Timely Access to Care Act. #PriorAuth
@ascocancer.bsky.social @weldeiry.bsky.social
@ascocancer.bsky.social @weldeiry.bsky.social
April 7, 2025 at 3:40 PM
#RhodeIsland’s own Anthony Mega engaging with the #ASCOAdvocacySummit team around ways oncology clinicians can advocate for prior authorization reform thru Improving Seniors Timely Access to Care Act. #PriorAuth
@ascocancer.bsky.social @weldeiry.bsky.social
@ascocancer.bsky.social @weldeiry.bsky.social
Hot tips from #ASCOAdvocacySummit #ASCOAdvocacy:
A Media Interview (or high profile meeting) is the WRONG TIME for an original thought. Stay on message! Come prepared.
Preach! 🙌🏻 🗣️
@ascocancer.bsky.social @lymphomadoc.bsky.social @ishwaria.bsky.social
A Media Interview (or high profile meeting) is the WRONG TIME for an original thought. Stay on message! Come prepared.
Preach! 🙌🏻 🗣️
@ascocancer.bsky.social @lymphomadoc.bsky.social @ishwaria.bsky.social
April 7, 2025 at 2:35 PM
Hot tips from #ASCOAdvocacySummit #ASCOAdvocacy:
A Media Interview (or high profile meeting) is the WRONG TIME for an original thought. Stay on message! Come prepared.
Preach! 🙌🏻 🗣️
@ascocancer.bsky.social @lymphomadoc.bsky.social @ishwaria.bsky.social
A Media Interview (or high profile meeting) is the WRONG TIME for an original thought. Stay on message! Come prepared.
Preach! 🙌🏻 🗣️
@ascocancer.bsky.social @lymphomadoc.bsky.social @ishwaria.bsky.social
Thanks, @ASCO for naming me an Advocacy Champion for my continued commitment to advocating for issues affecting the #oncology community. You can be an Advocacy Champion too by getting involved today: asco.org/actnetwork #ASCOAdvocacySummit
April 6, 2025 at 10:56 PM
Thanks, @ASCO for naming me an Advocacy Champion for my continued commitment to advocating for issues affecting the #oncology community. You can be an Advocacy Champion too by getting involved today: asco.org/actnetwork #ASCOAdvocacySummit
Identifying surrogate endpoints as valid, reliable primary endpoints is key to advancing cancer care. Partnered on this real-world data analysis demonstrating very strong, positive correlation between iDFS and OS @acsjournalcancer.bsky.social
acsjournals.onlinelibrary.wiley.com/doi/full/10....
acsjournals.onlinelibrary.wiley.com/doi/full/10....
April 3, 2025 at 11:28 AM
Identifying surrogate endpoints as valid, reliable primary endpoints is key to advancing cancer care. Partnered on this real-world data analysis demonstrating very strong, positive correlation between iDFS and OS @acsjournalcancer.bsky.social
acsjournals.onlinelibrary.wiley.com/doi/full/10....
acsjournals.onlinelibrary.wiley.com/doi/full/10....
Looking to include more advocate partners in your work, or train as an advocate yourself? @TanjaSpanic @EuropaDonnaSLO includes this list of for places to start. #SGBCC2025
March 14, 2025 at 12:49 PM
Looking to include more advocate partners in your work, or train as an advocate yourself? @TanjaSpanic @EuropaDonnaSLO includes this list of for places to start. #SGBCC2025
Meredith Regan proposes framework using established criteria for pragmatic clinical trial design, then walks audience thru process using PREPEC. #masterclass #SGBCC2025
March 14, 2025 at 12:19 PM
Meredith Regan proposes framework using established criteria for pragmatic clinical trial design, then walks audience thru process using PREPEC. #masterclass #SGBCC2025
May I ask more about your experience? There was an interesting presentation yesterday (I didn’t post) on the complicated, limited, conflicting data around patient satisfaction w/breast conservative vs mastectomy—and the variables that contribute which are difficult to account for scientifically
March 14, 2025 at 10:00 AM
May I ask more about your experience? There was an interesting presentation yesterday (I didn’t post) on the complicated, limited, conflicting data around patient satisfaction w/breast conservative vs mastectomy—and the variables that contribute which are difficult to account for scientifically
Christian Singer presents alternatives to bilateral mastectomy for risk reduction in women with BRCA pathogenic variant.
He cites benefits to effective screening (MRI), BSO, tamoxifen, and lifestyle modifications (specifically exercise & weight loss) as strategies.
#SGBCC2025 #brca
He cites benefits to effective screening (MRI), BSO, tamoxifen, and lifestyle modifications (specifically exercise & weight loss) as strategies.
#SGBCC2025 #brca
March 14, 2025 at 8:47 AM
Christian Singer presents alternatives to bilateral mastectomy for risk reduction in women with BRCA pathogenic variant.
He cites benefits to effective screening (MRI), BSO, tamoxifen, and lifestyle modifications (specifically exercise & weight loss) as strategies.
#SGBCC2025 #brca
He cites benefits to effective screening (MRI), BSO, tamoxifen, and lifestyle modifications (specifically exercise & weight loss) as strategies.
#SGBCC2025 #brca
Beyond ChatGPT and digital pathology algorithms, @jnkt.bsky.social reviews current and future states for deep learning artificial intelligence in breast oncology #SGBCC2025
March 13, 2025 at 3:23 PM
Beyond ChatGPT and digital pathology algorithms, @jnkt.bsky.social reviews current and future states for deep learning artificial intelligence in breast oncology #SGBCC2025
Marleen Kok @marleenkok.bsky.social had the difficult task of discussing the role of IO in HR+ breast cancer—she focused on ER-low disease, and suggests that we treat as TNBC. #SGBCC2025
March 13, 2025 at 2:46 PM
Marleen Kok @marleenkok.bsky.social had the difficult task of discussing the role of IO in HR+ breast cancer—she focused on ER-low disease, and suggests that we treat as TNBC. #SGBCC2025